Samsung Pharmaceutical삼성제약
001360 · KOSPI · ₩001360 · 삼성제약
- Market cap
- ₩118B
- Enterprise value
- ₩123B
- P/E
- —
- P/B
- 1.6×
- Dividend yield
- 0.0%
- ROE
- −189.8%
- Net margin
- −320.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−45.9% from the high
₩1,140Today: ₩1,252 – ₩1,286₩2,320
Returns
- 1W−4.3%
- 1M−4.1%
- 3M+0.4%
- 6M−40.7%
- YTD−18.0%
- 1Y−17.7%
- Volume today
- 152,933
- 0.4× the 20-day average
- Traded today
- ₩193M
- Listed shares
- 94,162,079
- EPS (12 months)
- −₩1,457
- Earnings yield −116.2%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 29 of 100 (50 is a normal day for this stock).
- MomentumFlat-4.1% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Samsung Pharmaceutical stock overview
Samsung Pharmaceutical (삼성제약, KRX: 001360) is listed on KOSPI, in the Biotech & Pharma sector. Samsung Pharmaceutical is a South Korean company that manufactures and sells prescription and over-the-counter drugs, health functional foods, and conducts biopharma development. Its shares closed at ₩1,254 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩118B.
Key facts
- Market cap
- ₩118B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- Samsung Pharmaceutical is a South Korean company that manufactures and sells prescription and over-the-counter drugs, health functional foods, and conducts biopharma development.
Quick answers about Samsung Pharmaceutical
- What does Samsung Pharmaceutical do?
- Samsung Pharmaceutical is a South Korean company that manufactures and sells prescription and over-the-counter drugs, health functional foods, and conducts biopharma development. Its prescription drugs include antibiotics and prostate treatments, sold domestically through contract sales organizations, while its over-the-counter and quasi-drug products such as Gas Myeongsu and Pantoa are supplied to pharmacies and convenience stores in Korea under exclusive supply agreements. The company is also developing GV1001 for pancreatic cancer, Alzheimer's disease and progressive supranuclear palsy, with its main operations based in Hwaseong and Hyangnam in Korea.
- What is the market cap of Samsung Pharmaceutical?
- The market capitalisation of Samsung Pharmaceutical was ₩118B at the close on Oct 27, 2026.
- Who are the largest shareholders of Samsung Pharmaceutical?
- According to the latest official filings, the largest reported holders are Gembax (10.47%, as of Jan 8, 2026); National Pension Service (0.27%, as of Dec 31, 2025); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.14%, as of Jul 31, 2026).
- When is the next earnings report from Samsung Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Samsung Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Samsung Pharmaceutical?
- Yes. The National Pension Service held 0.27% of Samsung Pharmaceutical shares as of Dec 31, 2025.
Company profile
Samsung Pharmaceutical is a South Korean company that manufactures and sells prescription and over-the-counter drugs, health functional foods, and conducts biopharma development. Its prescription drugs include antibiotics and prostate treatments, sold domestically through contract sales organizations, while its over-the-counter and quasi-drug products such as Gas Myeongsu and Pantoa are supplied to pharmacies and convenience stores in Korea under exclusive supply agreements. The company is also developing GV1001 for pancreatic cancer, Alzheimer's disease and progressive supranuclear palsy, with its main operations based in Hwaseong and Hyangnam in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 삼성제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 정성택 대표이사
- Founded
- Aug 1929
- Listed
- Jul 1975
- Listed shares
- 94,162,079
- Fiscal year ends
- Month 12
- Website
- www.sspharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Major management matter relevant to investorsSep 28, 2026
- Major management matter relevant to investorsSep 23, 2026
- Results of Rights Offering or Issuance of Equity-Linked Bonds, etc. (Voluntary Disclosure)Sep 11, 2026
- Convertible bond issue decisionSep 2, 2026
- 5%+ holding reportAug 25, 2026
Titles in Korean until English translations are added.
Also known as: Samsung Pharmaceutical / 삼성제약 / 001360 / KRX:001360
Source: KRX statistical information